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Abstract
 
MHC class I–restricted tumor antigens can be presented to CD8
 
 
 
 T cells by two distinct path-
ways: via direct and indirect presentation. The relative contribution of these two pathways to-
ward the initial activation of tumor antigen–specific CD8
 
 
 
 T cells and their subsequent tumor
rejection is still vigorously debated. Using a tumor model able to dissect the relative contribu-
tions of direct and indirect presentation, we show unequivocally the inefficiency of direct pre-
sentation and the essential requirement of indirect presentation for the priming of naive tumor
antigen–specific T cells leading to tumor rejection. Moreover, we characterize the essential en-
vironment under which indirect presentation occurs, and find efficient cross-priming of tu-
mor-specific CD8
 
 
 
 T cells in the complete absence of secondary lymphoid tissues. The inde-
pendence of this process from local lymph nodes is compromised, however, in the absence of
CD4
 
 
 
 T cell help. Therefore, our paper demonstrates that effective immune protection against
tumors requires the cross-priming of CD8
 
 
 
 T cells under conditions that require either CD4
 
 
 
T cell help, or draining lymph nodes.
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Introduction
 
The failure to prime tumor antigen–specific CD8
 
 
 
 T cells
may permit unchecked progression of immunogenic tu-
mors. How to enhance the priming of tumor-specific
CD8
 
 
 
 T cells leading to the eradication of an established
 
solid tumor has been a challenging issue. MHC class
I–restricted tumor antigens can be presented to CD8
 
 
 
 T
cells by two distinct mechanisms: (a) direct priming of CD8
 
 
 
T cells involves their engagement by cognate peptide–
MHC-I complexes of cells for which these presented antigens
are of their own production; and (b) cross-priming, or in-
 
direct priming, on the other hand, is mediated by host pro-
fessional APCs that take up and process antigens originally
synthesized by other cells. The contributions of these two
pathways to priming tumor-specific CD8
 
 
 
 T cells and their
pathophysiological relevance have been vigorously debated.
 
There is convincing evidence that exogenous proteins
can be a source of class I–restricted antigens (1–4). Seung
et al. have shown, for example, that MHC-deficient
tumors can stimulate the proliferation of naive tumor-spe-
cific CD8
 
 
 
 T cells, with the implication that cytolytic T
cells can be generated without direct antigen presentation
(5). Furthermore, Huang et al. have shown that bone
marrow (BM)
 
*
 
–derived cells are required for the priming
of cytolytic T cells against MHC-deficient tumors (6). In
contrast, other studies have reported that tumor cells ex-
pressing an antigenic peptide from a glycoprotein of lym-
phocytic choriomenigitis virus could generate cytolytic T
lymphocytes (CTL) via direct pathway but failed to induce
cross-priming (7–9). Moreover, using genetic models that
allow only one mode of antigen presentation, recent studies
have shown that both cross-presentation of the tumor anti-
gen by the host APCs and direct antigen presentation by
the tumor cells are sufficient to initiate rapid T cell clonal
expansion in the lymphoid organs (10). Understanding
how tumor antigen–specific CD8
 
 
 
 T cells are activated, by
direct or indirect presentation, has an important impact on
our understanding of how antigenic tumors escape recog-
nition by CD8
 
 
 
 T cells, and may shape design of therapeu-
tic regiments toward invigorating the cytolytic CD8
 
 
 
 T
cell response.
 
Address correspondence to Yang-Xin Fu, Dept. of Pathology, MC3083,
5841 S. Maryland, The University of Chicago, Chicago, IL 60637. Phone:
773-702-0929; Fax: 773-834-8940; E-mail: yfu@midway.uchicago.edu
 
*
 
Abbreviations used in this paper:
 
 BM, bone marrow; CFSE, carboxyfluores-
cein diacetate succinimidyl ester; CTL, cytolytic T lymphocytes; DC,
dendritic cells; DLN, draining LN; LN, lymph node; LT, lymphotoxin;
LT
 
 
 
R-Ig, LT
 
 
 
 receptor-Ig; NDLN, nondraining lymph node; SIY,
SIYRYYGL; TNFR55-Ig, TNF receptor-Ig; WT, wild-type.T
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Lymph Node-less Mice Require CD4
 
 
 
 T Cell Help for Tumor Rejection
 
Efficient priming of CD8
 
 
 
 T cells requires the intricate
yet robust orchestration of spatial and temporal interaction
among immune cells and microenvironments. Host profes-
sional APCs are capable of transporting antigens from pe-
ripheral tissues to secondary lymphoid organs, where they
meet rare antigen-specific lymphocytes. These compart-
mentalized secondary lymphoid organs, such as spleen and
draining lymph nodes (DLNs), provide the microenviron-
ment for optimal priming of naive lymphocytes (4, 11, 12).
It has been suggested that draining lymph nodes are key
sites for the direct priming of tumor antigen–specific CD8
 
 
 
T cells by tumor cells, and thus absolutely required for anti-
tumor immunity (7–9). CD8
 
 
 
 T cell responses can be di-
vided into CD4
 
 
 
 T cell–independent and CD4
 
 
 
 T cell–
dependent responses. CD4
 
 
 
 T cell–dependent type of
CD8
 
 
 
 T cell response revealed an important role for CD4
 
 
 
T cells in the activation of APCs and the generation of
memory CD8
 
 
 
 cells (13–16).
We have developed a tumor model that allows us to dis-
sect direct and indirect presentation pathways to elucidate
their relative contributions to CD8
 
 
 
 T cell priming and
subsequent tumor rejection. We transfected a fibrosarcoma
cell line MC57G originally derived from MC57BL/6 (B6)
mice (H-2
 
b
 
) with either L
 
d
 
 or an antigenic peptide
SIYRYYGL (SIY). In the B6 hosts, adoptively transferred
2C TCR transgenic T cells recognize L
 
d
 
 only through the
direct pathway, but can recognize the SIY peptide via both
direct and indirect pathways (17, 18). In our experiments,
carboxyfluorescein diacetate succinimidyl ester (CFSE)-
labeled 2C T cells were adoptively transferred into B6 mice
that were inoculated with either fibrosarcoma MC57G
transfected with L
 
d
 
 (MC57-L
 
d
 
) or SIY (MC57-SIY). Our
approach directly dissects early T cell priming and each step
of expansion, maturation, and ultimate tumor rejection to
address this critical question. By visualizing the early prolif-
eration and maturation of antigen-specific CD8
 
 
 
 T cells,
our data clearly shows that MC57-SIY, but not MC57-L
 
d
 
,
efficiently primes naive 2C T cells in draining lymphoid
tissue leading to tumor rejection. Furthermore, our paper
reveals that in the absence of DLN, CD8
 
 
 
 T cells become
dependent on CD4 help. These results suggest a comple-
mentary role of DLN and CD4 help in the priming CD8
 
 
 
T cells.
 
Materials and Methods
 
Mice, Cell Lines, and Reagents. 
 
Female C57BL/6 (B6) and
C57BL/6 Ly5.1 (B6/Ly5.1) congenic mice were purchased from
the National Cancer Institute, Frederick Cancer Research Facil-
ity. C57BL/6-Cd8
 
 
 
tm1Mak
 
 (CD8
 
 
 
/
 
 
 
) mice were purchased from
the Jackson Laboratory. 2C TCR transgenic mice on RAG-1–
deficient background bred into B6 background for 10 generations
(2C TCR transgenic mice) were provided by J. Chen (Massachu-
setts Institute of Technology, Boston, MA). OT-1 TCR trans-
genic mice were provided by A. Ma (The University of Chi-
cago). Lymphotoxin 
 
 
 
–deficient (LT
 
 
 
 
 
/
 
 
 
) mice were
backcrossed into B6 background for 10 generations. CD8
 
 
 
/
 
 
 
,
2C, OT-1 TCR transgenic, and LT
 
 
 
 
 
/
 
 
 
 mice were bred and
maintained in the specific pathogen-free facility at the University
 
of Chicago. Animal care and use were in accord with institutional
guidelines. For B6/Ly5.1, LT
 
 
 
 
 
/
 
 
 
, or B6/Ly5.1, B6 BM chime-
ras, LT
 
 
 
 
 
/
 
 
 
 or B6 mice were lethally irradiated with 9.5 Gy and
were 4-h later reconstituted with 5 
 
  
 
10
 
6
 
 B6/Ly5.1 BM cells.
BM chimeric mice were used in experiments after at least 6 wk
after reconstitution.
The MC57G fibrosarcoma cell line was provided by P. Ohashi
(University of Toronto, Toronto, Canada) and H. Hengartner
(University Hospital, Zurich, Switzerland; references 8, 9). All
tumor cell lines used in these experiments were maintained in
DMEM (Mediatech) supplemented with 10% FCS (Sigma-
Aldrich), 100 U/ml penicillin, and 100 µg/ml streptomycin (Bio-
Whittaker). The hybridoma cell lines producing anti-L
 
d
 
 (clone
30–5-7) and anti–2C TCR (1B2) antibodies were obtained from
D. Sachs (National Institutes of Health, Bethesda, MD) and T.
Gajweski (The University of Chicago), respectively. Monoclonal
antibodies produced by hybridomas were purified from the cul-
ture supernatant with protein G column by standard procedure.
The 1B2 antibody was conjugated to FITC or biotin by the
Monoclonal Antibody Facility of The University of Chicago.
PE-coupled anti-CD8
 
 
 
 antibody, PE-coupled anti-IFN
 
 
 
 anti-
body, isotype control PE-coupled rat IgG1 antibody, cy-chrome
(CyC)-coupled streptavidin, and CyC-coupled anti-CD44 anti-
body were purchased from BD Biosciences. FITC–conjugated-
anti–mouse IgG was purchased from Caltag. PE-coupled strepta-
vidin was purchased from Immunotech. Brefeldin A, ionomycin,
PMA, collagenase (type 4), and heparin were purchased from
Sigma-Aldrich. CFSE was purchased from Molecular Probes. Fi-
coll-paque was purchased from Amersham Biosciences.
 
Cell Isolation from Peripheral Blood and Lung. 
 
Peripheral blood
was collected from the retro-orbital plexus into tubes containing
100 µl of 20 U/ml heparin in PBS, and lymphocytes were puri-
fied by Ficoll-paque. For lung leukocyte isolation, the mice were
first bled to decrease the blood contamination of lung tissue. The
lungs were collected, washed in the PBS, cut into pieces, and re-
suspended in DMEM supplemented with 2% FCS and 1.25 mg/
ml collagenase D (collagenase D solution) for 20 min in a 37
 
 
 
C
shaking incubator. The single cell suspension was collected after
20 min, and the cell clumps were digested for another 20 min in
the collagenase D solution until all lung tissue had resolved into a
single cell suspension.
 
Generation of SIY and L
 
d
 
 Expression Vectors and Clones (19).
 
In brief, to generate pcDNA3.1-L
 
d
 
, the LK444 plasmid contain-
ing L
 
d
 
 cDNA (provided by A. Sant, The University of Chicago)
was digested with EcoRI and ligated to an EcoRI-digested, calf
intestinal phosphatase–treated pcDNA 3.1 (Invitrogen). To gen-
erate iSIY–LEGFP, an SlY minigene was made from two dsDNA
oligonucleotides (SIY-5
 
 
 
 and SIY-3
 
 
 
) annealed, phosphorylated,
and ligated together. SIY-5
 
 
 
 was made by annealing 5
 
 
 
-
 
TCGA-
 
CGCCACCATGGTGTCTATTTACAGGTACTACGGCCT-
GGCTGCTTACTCTATTTACA-3
 
 
 
 with 5
 
 
 
-TACCTGTAA-
ATAGAGTAAGCAGCCAGGCCGTAGTACCTGTAAATA-
GACACCATGGTGGCG-3
 
 
 
. SIY-3
 
 
 
 was made by annealing
5
 
 
 
-GGTACTACGGCCTGGCTGCTTACTCTATTTACAG-
GTACTACGGCCTGGCTGCTTACGGG-3
 
 
 
 with 5
 
 
 
-
 
GAT-
C
 
CCCGTAAGCAGCCAGGCCGTAGTACCTGTAAATAG-
AGTAAGCAGCCAGGCCGTAG-3
 
 
 
. The boldface indicates
SalI and BamHI overhangs for SIY-5
 
 
 
 and SIY-3
 
 
 
, respectively;
the underlined base pairs indicate the overhang of SIY-5
 
 
 
, which
is complementary with the overhang of SIY-3
 
 
 
. The SIY mini-
gene was ligated to a SalI–BamHI fragment of pLEGFP (CLON-
TECH Laboratories, Inc.), generating SIY-LEGFP. To generate
pcDNA-SIY, SIY-LEGFP was digested with EcoRI–BamHI,T
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and the fragment containing the SIY peptide was ligated to an
EcoRI–BamHI fragment of pcDNA3.1. The EGFP gene was
generated by PCR with the primers 5
 
 
 
-GGGGATCCAGGCG-
GCGGCATGGTGAGCAAG-3
 
 
 
 and 5
 
 
 
-CCAAGCTTCATT-
GATGAGTTTGGACAAACC-3
 
 
 
. This EGFP PCR product
was digested with BamHI and HindIII and ligated to a BamHI–
HindIII fragment of pcDNA3.1-SIY to generate the vector
pcDNA3.1-SIY-EGFP.
To generate MC57-L
 
d
 
, MC57-SIY, and MC57-EGFP,
MC57G cells were transfected with pcDNA3.1-L
 
d
 
, pcDNA3.1-
SIY-EGFP, or pcDNA3.1-EGFP using Superfect (QIAGEN). 48 h
after transfection, the cell lines were treated with 1 mg/ml G418
and cloned by limiting dilution.
 
Analysis of Cells by FACS
 
®
 
. 
 
For analysis of L
 
d
 
 expression,
tumor cells were incubated with the anti-L
 
d
 
 antibody, washed,
and incubated with FITC-coupled anti–mouse IgG antibody.
For detection of proliferation of CFSE-labeled 2C T cells, iso-
lated lymph node (LN) cells, splenocytes, and cells from periph-
eral blood and lung were stained with biotinylated 1B2 anti-
body, washed, and stained with CyC-coupled streptavidin and
PE-coupled anti-CD8
 
 
 
. For analysis of CFSE-labeled 2C T
cells and CD44 expression, isolated LN cells or splenocytes
were stained with biotinylated 1B2 antibody, washed, and
stained with a mixture of PE-coupled streptavidin and CyC-
coupled anti-CD44. For analysis of IFN-
 
 
 
 production, isolated
LN cells or splenocytes were incubated with 50 ng/ml PMA,
500 ng/ml ionomycin, and 10 
 
 
 
g/ml Brefeldin A for 4 h in
complete RPMI 1640 (Mediatech) at 37
 
 
 
C. The cells were
washed and stained with biotinylated 1B2, washed, and stained
with CyC-coupled streptavidin. The cells were fixed with 4%
paraformaldehyde and permeabilized with 0.5% saponin in PBS
with 1% BSA and 0.1% azide. The cells were stained with
PE-coupled anti-IFN
 
 
 
 or the isotype control. Samples were
analyzed on a FACScan™ and data was analyzed with
CELLQuest™ software.
 
Adoptive Transfer of 2C T Cells. 
 
LN cells and splenocytes
were isolated from 2C mice and CD8
 
 
 
 T cells were negatively
selected with a CD8
 
 
 
 T cell enrichment kit (StemCell Technolo-
gies, Inc.). When analyzed, 
 
 
 
90% of the enriched CD8
 
 
 
 cells
expressed the 2C receptor. Approximately 7–9 
 
  
 
10
 
5
 
 2C T cells
were transferred into CD8-deficient mice for assays of tumor
growth. The same number of 2C T cells were transferred to each
mouse in each experiment. To transfer CFSE-labeled T cells, T
cells at a concentration of 2 
 
 
 
 10
 
7
 
/ml were labeled with 10 µM
CFSE in PBS at 37
 
 
 
C for 30 min. The cells were quenched with
equal volume of FCS for 1 min and washed three times, and 3 
 
 
 
10
 
6
 
 CFSE-labeled T cells were injected intravenously into the
retro-orbital plexus in a 0.2-ml volume. The next day, mice were
challenged subcutaneously with tumor cell suspensions 
 
 
 
0.5
 
 
 
cm
above the tail base. Cells were isolated from the inguinal lymph
nodes (DLNs), the other lymph nodes (nondraining lymph nodes
[NDLN]), peripheral blood, lung, or spleen at the time indicated.
Data for 2C T cell responses to challenges of tumor cells are rep-
resentative of at least three experiments.
 
51
 
Cr Release Assay. 
 
To compare the cytolytic activity of T
cells from MC57-L
 
d
 
– or MC57-SIY–challenged mice, spleen
cells were incubated with mitomycin C–treated MC57-L
 
d or
MC57-SIY tumor cells, respectively, in a mixed lymphocyte-
tumor cell culture as described previously (20). The cytotoxicity
of mixed lymphocyte-tumor cell culture effector cells was deter-
mined in a 4.5-h 51Cr release assay at different effector-to-target
ratios as described previously (20). The percent-specific lysis was
calculated by the formula: percent lysis   ([experimental release  
spontaneous release]/[maximum release   spontaneous release])  
100. Spontaneous release was  15% of maximum. Maximum re-
lease was determined by detergent lysis of targets.
LN Ablation Protocol.  To ablate peripheral LN development,
pregnant female C57BL/6 mice were injected intravenously with
100 µg of purified murine LT  receptor-Ig (LT R-Ig) on gesta-
tion day 12. To ablate all LN, including peripheral and mucosal
LN, pregnant female C57BL/6 mice were treated with the com-
bination of 100 µg each of TNF receptor-Ig (TNFR55-Ig) and
LT R-Ig before gestation day 11 (21). The presence or absence
of mucosal and/or peripheral LN was carefully determined by
dissection of representative progeny of each litter, and confirmed
in each individual animal at necropsy.
Results
Direct Presentation Was Not Sufficient, Whereas Cross-pre-
sentation Was Essential for the Induction of Tumor Antigen–spe-
cific CD8  T Cell Proliferation.  It has been proposed that
direct priming of CD8  T cells in the DLN is essential for
the rejection of MC57G, whereas indirect presentation is
insignificant (8, 9). To elucidate the importance of direct
and indirect presentation in the priming of CD8  T cells,
we developed a tumor model in which we can separate
these two distinctive pathways. MC57G cells were trans-
fected with either pcDNA3.1-Ld (MC57-Ld; Fig. 1 B) or
pcDNA3.1-SIY-EGFP (MC57-SIY; Fig. 1 C). As the con-
trol, MC57G was transfected with pcDNA3.1-EGFP
(MC57-EGFP; Fig. 1 A). An SIY expression construct was
made by fusing three copies of the SIY minigene to the
EGFP gene, which was used to quantify the level of anti-
gen expression (Fig. 1 C). The SIY peptides were separated
by three amino acid spacers to favor correct processing of
this antigen (22–24). MC57-SIY expression of EGFP and
MC57-Ld expression of Ld were confirmed by FACS® (Fig.
1 D). Ld expression on MC57-Ld was comparable to that
found naturally on mastocytoma P815 (unpublished data).
In B6 mice (haplotype H-2b), adoptively transferred 2C T
cells can recognize MC57-Ld only via direct antigen pre-
sentation, whereas they can recognize MC57-SIY via both
direct and indirect pathways (17, 18).
To trace the location and the progress of T cells prim-
ing, CFSE-labeled 2C T cells were transferred into B6
mice followed by a subcutaneous challenge with MC57-Ld
cells 24 h after T cell transfer. 2, 4, and 7 d after the tumor
challenge, very limited proliferation of CFSE-labeled 2C
T cells was observed in the DLN, other NDLN, or
spleen (Fig. 1 F). In contrast, subcutaneous inoculation of
MC57-SIY induced vigorous antigen-specific 2C T cell
proliferation in the DLN 4 d after the challenge (Fig. 1
G). Activated 2C T cells migrated to other NDLNs and
spleen to continue proliferation. The proliferative re-
sponse of CFSE-labeled 2C T cells to MC57-SIY was not
due to EGFP because mice identically challenged with
MC57-EGFP showed no proliferation (Fig. 1 E). Consis-
tent with these findings, we noted that 2C T cells re-
sponded to MC57-SIY, but not MC57-Ld, by prolifera-
tion, up-regulation of activation marker CD44 (Fig. 1 H),
and secretion of IFN-  (Fig. 1 I). Using CFSE-labeled 2CT
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T cells, we find that the priming of these CD8  T cells in
the lymphoid tissues is antigen- and TCR-specific: (a)
MC57-SIY does not induce proliferation of OT-I trans-
genic T cells (unpublished data); and (b) 2C T cells do not
respond to MC57-EGFP (Fig. 1 E). Thus, direct presenta-
tion alone was not sufficient to prime antigen-specific
CD8  T cells, whereas indirect presentation was required
to specifically prime T cells leading to proliferation and
gain of effector function.
Only the Tumor Expressing Antigen That Can Be Cross-pre-
sented Was Rejected.  CD8  T cells are critical for the re-
jection of MC57G because MC57G tumor cells grow
progressively in CD8  T cell–depleted B6 mice and CD8-
deficient mice. Most tumors, including MC57G, bear mul-
tiple antigens and induce polyclonal CD8  T cell responses
that obfuscate clear analysis of contribution by direct or in-
direct presentation for tumor rejection. To ensure a clearly
dissectable monoclonal response, we used CD8-deficient
B6 mice reconstituted with 7–9   105 naive 2C T cells. In
contrast to Rag-1 /  recipients, CFSE-labeled naive 2C T
cells did not undergo homeostasis proliferation in the
CD8 /  mice within 2 wk of constant observation after
adoptive transfer (unpublished data). MC57-SIY and
MC57-Ld growth was equally aggressive in the CD8-defi-
cient mice (Fig. 2 A and Table I). Activated 2C T cells lysed
MC57-Ld and MC57-SIY with similar efficiency in vitro,
demonstrating comparable levels of direct presentation (un-
published data). To better trace the priming status of mono-
clonal tumor-specific CD8  T cells in response to a de-
fined antigen and their ability to reject the tumors, 107
MC57-SIY or MC57-Ld tumors were inoculated into
CD8-deficient B6 mice, followed by adoptive transfer of
7–9   105 2C T cells 7 d later. Consistent with the earlier
priming experiments, only MC57-SIY was rejected when
2C T cells were transferred (Fig. 2 B and Table I), whereas
the MC57-Ld grew progressively even in the presence of
2C T cells (Fig. 2 B and Table I). Thus, direct antigen pre-
sentation alone appears insufficient for tumor rejection.
The rejection of MC57-SIY by 2C T cells is antigen-spe-
cific because the same number of, or more irrelevant, OT-I
T cells did not reject MC57-SIY tumor cells (Fig. 2 C).
Furthermore, tumor-specific antigen SIY is required for
the rejection by 2C T cells because antigen-negative con-
trol tumors, MC57G and MC57-EGFP, grew progres-
sively in the 2C T cell–reconstituted CD8-deficient mice
(Table I). This demonstrates that only antigen, expressed
on a tumor that can be cross-presented, leads to tumor re-
jection. Moreover, antigen on tumor cells that can only be
directly presented was not sufficient to prime T cells nor
cause rejection.
Directly Presented Antigen on Tumors Is Sufficient for the Re-
jection by Activated T Cells.  We hypothesized that failure
to reject MC57-Ld tumor is likely to be due, at least in
part, to the lack of priming. To further dissect whether it is
the priming or the effector phase at which the MC57-Ld
tumor cells fail to be rejected by 2C T cells, MC57-SIY,
and MC57-Ld tumor cells were inoculated on the two
flanks of a single CD8-deficient mouse. Given earlier find-
ings, MC57-SIY tumor cells initiate robust 2C T cell
priming, and if indeed MC57Ld progression is due to its
failure to prime 2C T cells, then under these conditions
MC57Ld should be rejected with the same kinetics as
MC57-SIY. As controls, we injected MC57-SIY and
MC57G, or MC57-EGFP and MC57Ld on the two flanks
of the control mice. 2C T cells from TCR transgenic mice
were purified and 7–9   105 were transferred on day seven
into the mice bearing MC57-SIY and MC57-Ld tumors
on each flank or the control mice. Remarkably, both
Figure 1. Subcutaneous chal-
lenge of MC57-SIY, but not
MC57-Ld, induced proliferation and
activation of 2C T cells. MC57G
tumor cells were transfected with
pcDNA-EGFP (A), pcDNA-Ld (B),
or pcDNA-SIY-EGFP (C). MC57-Ld
and MC57-SIY expressed Ld and
EGFP, respectively (D). 3   106
CFSE-labeled 2C T cells were trans-
ferred into B6 mice. 24 h later, these
mice were challenged with 106
MC57-SIY, MC57-Ld, or MC57-
EGFP above the tail base. MC57-
SIY–induced proliferation (G),
up-regulation of CD44 (H), and
secretion of INF-  (I) of 2C T cells
96 h after tumor challenge in the
DLN, NDLN, and spleen. However,
MC57-EGFP (E) and MC57-Ld (F)
failed to cause any proliferation, up-
regulation of CD44 (H), and pro-
duction of INF-  (I).T
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MC57 tumors, expressing either SIY or Ld antigen, were
rejected (Fig. 2 E and Table I). The MC57G parental tu-
mor on the opposite flank of the MC57-SIY tumor grew
progressively (Fig. 2 E and Table I), whereas MC57-Ld in-
jected on the opposite flank of MC57-EGFP grew at the
same rate as MC57-Ld (Fig. 2 E and Table I). To deter-
mine whether these two lines (MC57-SIY and MC57-Ld)
are equally sensitive to 2C T cell effector functions, the
splenocytes from the 2C T cell–reconstituted CD8-defi-
cient mice primed with MC57-SIY for 4 wk were
collected and cultured with irradiated MC57-SIY or
MC57-Ld for 6 d for an in vitro 51Cr release assay. We
found that T cells from mice that had been primed with
MC57-SIY lysed MC57-SIY and MC57-Ld equally well,
though MC57G parental cell lines were undisturbed (Fig.
2 D). However, the T cells from mice challenged with
MC57-Ld could not lyse either MC57-Ld or MC57-SIY in
vitro (Fig. 2 D). In our work, we found the priming and
expansion of antigen-specific T cells paralleled with func-
tional maturation measured by IFN  production. Given
the earlier finding that MC57-Ld caused very limited pro-
liferation of 2C T cells, the failure of this recall response is
likely due to the lack of priming, expansion, and functional
maturation at an early stage of T cell activation, rather than
only deficiency in elicitation of memory activity during
the in vitro restimulation. The results of these experiments
demonstrate both the necessity of cross-presentation for
tumor antigen–specific CD8  T cell activation, and di-
rectly presented antigen on tumors is sufficient for the re-
jection by activated T cells.
Direct Priming of CD8  T Cells Inside the Secondary Lym-
phoid Organ.  Lack of priming and failure of rejection of
MC57-Ld tumor via subcutaneous injection can be attrib-
uted to either poor direct antigen presentation or the lack
of proper antigens on tumor cells to prime 2C T cells for
rejection. To exclude the second possibility, we investi-
gated whether direct priming of 2C T cells by MC57-Ld
can occur under ideal conditions, i.e., when T cells en-
counter significant numbers of MC57-Ld tumor cells in the
secondary lymphoid tissue. Mice were inoculated subcuta-
neously with 107 MC57-Ld, or MC57G parental tumor
cells. 7–9   105 2C T cells were adoptively transferred 7 d
after tumor inoculation. 24 h later, 106 MC57-Ld tumor
cells were directly inoculated into the spleen of these mice.
As controls, we injected 106 MC57G parental tumor cells
into the spleens of the mice with or without 2C T cell
transfer. Transferred 2C T cells primed intrasplenically with
106 MC57-Ld cells indeed were able to reject the subcuta-
neous MC57-Ld tumors (Fig. 2 F). The tumors in the con-
trol groups all grew out progressively (Fig. 2 F). These re-
sults are consistent with previous findings (9, 25) and
demonstrate that large numbers of the MC57-Ld tumor
cells are able to directly prime 2C T cells in the secondary
lymphoid tissue. Thus, there is no intrinsic defect in these
tumor cells to prime 2C T cells and the failure of rejection
of MC57-Ld were likely attributed to ineffective priming
by subcutaneously growing tumors.
Secondary Lymphoid Organs Were Not Essential for Tumor
Rejection.  Draining lymph nodes have been proposed to
be essential for the rejection of MC57G (9). To examine
Figure 2. MC57-SIY  but not
MC57-Ld tumors were rejected by naive
2C T cells. MC57 tumors were inocu-
lated to CD8-deficient mice. 7–9   105
2C, OT-1, or no T cells as indicated
were transferred into these mice 1 wk
after tumor injection. (A) MC57-SIY and
MC57-Ld both grew progressively in
CD8-deficient mice. (B) Adoptively
transferred 2C T cells rejected MC57-
SIY but not MC57-Ld. (C) Both MC57-
SIY and MC57-Ld grew progressively in
the presence of OT-1 T cells. (D) CTL
from MC57-SIY–challenged mice lysed
both MC57-SIY and MC57-Ld equally
well in 51Cr release assay. However, CTL
from MC57-Ld–challenged mice lysed
neither. (E) MC57-SIY and MC57-Ld
tumors were inoculated to each flank of
the same mouse. As controls, MC57-SIY
and MC57G, or MC57-EGFP and
MC57-Ld, were inoculated the same way
to the mouse. MC57-Ld tumors were re-
jected by 2C T cells in the presence of
MC57-SIY. MC57G grew progressively
when MC57-SIY tumors on the same
mouse were rejected by 2C T cells.
MC57-EGFP and MC57-Ld both grew
in the presence of 2C T cells. (F) MC57-Ld
tumors were rejected when 2C T cells
were primed by intrasplenic injection of
106 MC57-Ld cancer cells.T
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if draining lymph nodes are essential for immune re-
sponses when tumor antigens can be cross-presented, lym-
photoxin (LT)  -deficient B6 mice were used. LT -defi-
cient mice lack all the lymph nodes and Peyer’s patches
and have disorganized splenic structures. We challenged
B6 wild-type (WT) and LT -deficient mice with titrated
doses of MC57G, MC57-EGFP, MC57-Ld, or MC57-
SIY tumor cells ranging from 107 to 108, and then com-
pared their growth. Even though tumors were eventually
rejected in the LT -deficient mice (Table I), the rejection
was noticeably delayed relative to WT mice (Fig. 3 A).
To isolate the site of priming in mice devoid of all the
lymph nodes, CFSE-labeled 2C T cells were adoptively
transferred into LT -deficient mice and MC57-SIY tu-
mor cells were inoculated the next day. 2C T cell prolif-
eration in LT -deficient mice is antigen-dependent be-
Table I. Incidence of MC57 Tumors in Experiments
Treatment
Mice Tumor injected 2C Tumor incidence (%)a 2C priming
CD8 /  MC57G 6/6 (100)
EGFP 6/6 (100)
Ld 12/12 (100)
SIY 12/12 (100)
MC57G Yes 6/6 (100) No
EGFP Yes 6/6 (100) No
Ld Yes 12/12 (100) No
SIY Yes 0/12 (0) Yes
Ldw/SIYb Yes 0/9 (0) Yes
Ldw/EGFPb Yes 6/6 (100) No
MC57Gw/SIYb Yes 6/6 (100) No
CD4 depletion
WT MC57G 0/6 (0)
EGFP 0/6 (0)
Ld 0/6 (0)
SIY 0/12 (0)
SIY Yes 0/12 (0)
Splenectomized WTc SIY 0/9 (0)
Splenectomized LT / c SIY 0/9 (0)
LT / -WT BM chimera SIY 0/6 (0)
Splenectomized
LT / -WT BM chimerac SIY 0/3 (0)
LT /  SIY 0/12 (0)
SIY Yes 9/9 (100)
LN-less WT SIY 0/9 (0)
SIY Yes 6/6 (100)
Splenectomized
LN-less WTc SIY 0/3 (0)
aThe number in parentheses reflects the pooled experiments with three mice per group.
bMice were challenged with tumor indicated on opposite flanks.
cSplenectomized mice were used in the experiment at least 10 days after surgery.T
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cause SIY-negative control tumor cells MC57-EGFP
failed to induce it (Fig. 3 C). We found proliferating 2C
T cells in the spleen of LT -deficient mice (Fig. 3 B).
The priming of 2C T cells in the spleen of LT -deficient
was slightly delayed in comparison with the WT mice in
the draining lymph nodes (Fig. 3 B). To exclude the pos-
sibility that cell-intrinsic defects in LT -deficient mice,
rather than lymph node agenesis, is responsible for delayed
rejection, LT -deficient mice were lethally irradiated and
reconstituted with congenic marker Ly5.1  WT BM. The
reconstitution of LT  /  BM by WT BM is approaching
100%, as estimated by the percentage of Ly5.1  cells
present in the peripheral blood in comparison to Ly5.1 
B6 donors (unpublished data). These WT-LT  /  BM
chimeras lack all the LNs and Peyer’s patches but have LT
from WT BM–derived cells. These chimeric mice were
inoculated with MC57-SIY tumor cells. Similar to LT -
deficient mice, they also rejected tumors in a slightly de-
layed fashion compared with WT mice or WT-WT BM
chimeras controls (Fig. 3 A and Table I). We also gener-
ated mice lacking peripheral lymph nodes (LN-less WT
mice) by blocking LT R signaling during gestation days
with LT  R–Ig. These mice have retained only mucosal
lymph nodes, though they have normal splenic structure
and immune response (21, 26). These LN-less WT mice
were also able to reject MC57-SIY with kinetics similar to
LT  /  mice (Fig. 3 A and Table I). Together, the data
showed that draining lymph nodes are not essential for
priming T cells when the antigen can be efficiently cross-
presented in secondary lymphoid tissues other than DLN,
such as the spleen.
To investigate whether (a) the spleen is essential, (b) the
spleen is the only alternative site, or (c) secondary
lymphoid organs are required for cross-priming, sple-
nectomized LT  /  and WT mice were generated and
challenged subcutaneously with 2   107 MC57-SIY. Sple-
nectomy did not hinder tumor rejection by WT mice,
suggesting that the spleen is dispensable for tumor rejection
in the presence of DLNs (Fig. 3 A and Table I). Splenecto-
mized LT  /  mice lacking all secondary lymphoid tissues
were still able to reject the tumors (Table I), though with
delayed kinetics relative to eusplenic LT  /  mice (Fig. 3
A). To exclude the possibility that cell-intrinsic defects in
splenectomized LT  /  mice, rather than a lack of second-
ary lymphoid organs, are responsible for the delayed and
ultimate tumor rejection, we challenged splenectomized
WT-LT  /  BM chimeras with 2   107 MC57-SIY tu-
mor cells. These mice that were deficient of all the second-
ary lymphoid organs were able to reject the tumor similarly
to splenectomized LT  /  mice (Table I). We also gener-
ated mice lacking all the lymph nodes, including peripheral
and mucosal ones, by blocking LT R and TNF receptor-I
signaling at the same time during early gestation days with
LT R–Ig and TNFR55–Ig. These mice did not have any
lymph nodes, though they have normal splenic structure
and immune response (21, 26). These splenectomized LN-
less WT mice were also able to reject MC57-SIY similarly
to splenectomized LT  /  mice (Table I). Thus, we con-
Figure 3. Tumor antigen–specific
T cells proliferated and rejected the
tumors in the absence of LN and
spleen. 2   107 MC57-SIY tumors
were inoculated to WT, splenecto-
mized WT, LT-deficient (LTKO),
LN-less WT, WT LT-deficient BM
chimeric mice, and splenectomized
LT-deficient mice and rejected by
these mice (A). 3   106 CFSE-labeled
2C T cells were transferred to B6,
LT-deficient B6, or splenectomized
LT-deficient B6 mice. MC57-SIY tu-
mor cells were inoculated 24 h later
and induced 2C T cell proliferation
and up-regulation of CD44 in both
WT and LT-deficient mice. 2C T cells proliferated in the spleen of LT-deficient mice with reduced kinetics comparing to those in WT mice (B).
MC57-EGFP tumor cells, which were inoculated the same way as MC57-SIY, did not cause proliferation of 2C T cells in the LT-deficient mice (C).
Proliferated 2C T cells can be detected in the peripheral blood of splenectomized LT-deficient mice and some proliferating 2C T cells were present in
the lung of these mice (D).T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
992 Lymph Node-less Mice Require CD4  T Cell Help for Tumor Rejection
clude that secondary lymphoid organs are not an absolute
requirements for the initial priming of protective anti-
tumor responses in immune competent individuals.
Proliferating T Cells Can Be Detected in the Lung in the Ab-
sence of Secondary Lymphoid Organs.  The rejection of
MC57-SIY is dependent on the activation of CD8  T
cells. To address if and where CD8  T cells are primed in
the absence of secondary lymphoid tissues, we traced the
priming of adoptively transferred 2C T cells as a marker for
endogenous tumor antigen–specific T cell clones respond-
ing to MC57-SIY. 10 d after LT -deficient mice were
splenectomized, they received 3   106 CFSC-labeled 2C
T cells. MC57-SIY tumor cells were inoculated subcutane-
ously 1 d later. Lung tissues were collected 2, 5, and 6 d af-
ter tumor inoculation and digested by collagenase. Purified
leukocytes were subjected to flow cytometry analysis. In-
terestingly, proliferating 2C cells could be readily detected
(Fig. 3 D), suggesting that antigen-specific CD8  T cells
were primed in the absence of all the secondary lymphoid
tissues. Also, there is the possibility that indirect priming of
CD8  T cells might happen in the peripheral tissues such as
lung in the absence of secondary lymphoid organs. It is
possible that delayed proliferation in the periphery may
lead to delayed rejection, as seen in Fig. 3 A. Therefore,
secondary lymphoid organs, although perhaps providing
the ideal environment for cross-priming, can in some cases
be dispensable.
The Role of CD4 Help for Cross-priming of CD8  T Cells
in the Spleen versus LN. The importance of CD4  T cells in
promoting an effective CD8  T cell response is well estab-
lished. Recent studies suggest that the mechanism by
which CD4  T cells accomplish such “help” is through
the activation of APCs (13–15). The rejection of MC57-
SIY by CD8  T cells can be CD4 help–independent (Fig.
4 A and Table I), and substantively independent of sec-
ondary lymphoid tissues. Because the priming of CD8  T
cells in this model is predominantly dependent on the
cross-presentation of antigen by host APCs, this suggests to
us that antigen-carrying APCs were able to migrate not
only to the DLN but also to the spleen and some other pe-
ripheral tissues to prime CD8  T cells. To investigate if
CD4 help is essential for this process, CD4  T cells were
depleted in WT and LT -deficient mice by anti-CD4 an-
tibody GK1.5, followed by subcutaneous inoculation of
107 MC57-SIY tumor cells. CD8  T cells were able to re-
ject MC57-SIY tumor cells independently of CD4  T cell
help in WT mice (Fig. 4 A and Table I). However, in
LT -deficient mice, 107 MC57-SIY tumor cells grew un-
checked with the depletion of CD4  T cells (Fig. 4 A and
Table I). To further address whether it is the priming or
effector phase that is compromised, CFSE-labeled 2C T
cells were adoptively transferred into B6 and LT -defi-
cient mice after CD4  T cell depletion, and recipients
were challenged with MC57-SIY the next day. 2, 4, and
5 d after the tumor challenge, spleens from these mice were
collected and CFSE-labeled 2C T cell proliferation was
evaluated. We found that whereas 2C T cells proliferated
robustly in the spleen of LT -deficient mice, they failed to
do so in the absence of CD4  T cells (Fig. 4 B). In con-
trast, 2C T cells proliferated in the DLN of WT mice at
Figure 4. Tumor antigen–spe-
cific T cells failed to proliferate and
reject the tumors in the absence of
DLN and CD4  T cells. (A) 107
MC57-SIY tumor cells were re-
jected in WT mice but not in the
LT-deficient mice (LTKO) or LN-
less WT mice in the absence of
CD4  T cells. (B) 3   106 CFSE-
labeled 2C T cells were transferred
to WT, CD4-depleted WT, LT-
deficient, CD4-depleted LT-defi-
cient, WT-LT /  BM chimera,
CD4-depleted WT-LT /  BM chi-
mera, LN-less, or CD4-depleted
LN-less B6 mice. MC57-SIY tumor
cells were inoculated 24 h later. 2C
T cells proliferated in WT, CD4-
depleted WT, LT-deficient, WT-
LT /  BM chimera, and LN-less B6
mice but failed to do so in the CD4-
depleted LN-devoid mice.T
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comparable levels with or without CD4 help (Fig. 4 B).
We compared the rate of proliferation of CFSE-labeled
2C T cells in the WT DLN and CD4 knockout mice to
similar results (unpublished data).
To exclude any BM cell-intrinsic defects from LT  de-
ficiency, both WT-LT  /  BM chimeras and LN-less
WT mice that lacking all the LN were used and yielded
the same results. CFSE-labeled 2C T cells failed to prolif-
erate in the spleen of WT-LT  /  chimeras without
CD4  T cells (Fig. 4 B). Similarly, in the LN-less WT
mice, we detected a drastically diminished proliferation of
CFSE-labeled 2C T cells in the absence than in the pres-
ence of CD4 help (Fig. 4 B). The findings in the prolifera-
tion assays paralleled the tumor rejection by endogenous
normal repertoire of CD8  T cells in these lymphoid or-
gan-deficient mice. LN-less WT mice lacking all the LN
failed to reject 107 MC57-SIY tumor cells after depletion
of CD4  T cells. Even LN-less WT mice with mucosal
LN and normal splenic structure were not able to reject
tumors without CD4 help (Fig. 4 A and Table I). There-
fore, we conclude that CD4  cells play an essential role in
the cross-priming of CD8  cells in the spleen, but not in
the DLN.
Discussion
We used a unique tumor model in which direct antigen
presentation by tumor cells can be distinguished from
cross-presentation to study the relative contributions of the
two pathways to tumor antigen–specific T cell priming for
tumor rejection. We show that direct presentation is very
inefficient for this process when examined in isolation of
cross-priming. Interestingly, we find in this cross-priming
dominant model that helper T cells are not required for the
priming of CD8  T cells in the draining lymph nodes but
are essential for that in the spleen. Therefore, we would ar-
gue that the interactions of CD4  T cells, CD8  T cells,
and APCs are orchestrated uniquely to facilitate efficient
priming disparate microenvironments (like the DLN),
other secondary lymphoid tissues, or peripheral sites.
The importance of different modes of antigen presenta-
tion for the priming of CD8  T cells is still vigorously de-
bated. The low frequency of antigen-specific T cells has
made analysis difficult. Previous studies on importance of
direct versus cross-priming of CD8  T cells evaluated ef-
fector and memory responses assayed in in vitro culture (6,
8, 9). Other factors may complicate such conclusions. CD4
help is important for the maintenance of CD8  T cell
memory response (16, 27). The production of CD8  effec-
tor and memory response differs in their requirements (28).
Moreover, the irradiation BM chimera model used by
other papers (6, 9) may be complicated by the fact that na-
ive T cells may require the restricting MHC element to
survive (29). Furthermore, it is difficult to study the relative
contribution of direct and indirect presentation on a back-
ground of polyclonal CD8  T cell responses to multiple
undefined antigens. Further study using monoclonal trans-
genic T cells clearly showed that both direct and indirect
presentations of the same antigenic epitope derived from
P1A can lead to activation of tumor antigen P1A–specific
CD8  T cells (10). However, whether such activation suf-
ficiently leads to ultimate tumor rejection is not clear. To
be able to trace a monoclonal population of tumor anti-
gen–specific naive CD8  T cells, visualized beginning at
the very early stages and every step of their response, and
followed to eventual tumor rejection, we have developed a
tumor system that permits monoclonal responses either in
whole, or in isolation of cross-priming. We studied how
and where these monoclonal CD8  T cells (2C) were
primed in response to a defined antigen leading to tumor
rejection that was dependent on their activation. We have
revealed that subcutaneous challenge of MC57G-bearing
antigen SIY, which can be cross-presented, induced prolif-
eration and maturation of 2C T cells leading to tumor re-
jection. However, subcutaneously growing MC57G-bear-
ing antigen Ld, which can only be direct-presented, failed
to do so. It has been reported that MC57G tumor cells mi-
grate to DLN (7–9). We could detect tumor cells in the
DLN by RTPCR (unpublished data). However, these me-
tastasized tumor cells were not sufficient to induce priming.
Only when we injected a large amount of MC57Ld tumor
cells directly into the secondary organs did they prime 2C
T cells. Thus, our data suggest that direct priming alone is
very inefficient to prime T cells. Cross-priming is domi-
nant in this model and may be dominant under the physio-
logical conditions.
Secondary lymphoid organs are widely understood to be
the nexus of initial antigen presentation to various lympho-
cytes for adaptive immune reaction to antigens (11, 12).
Dependence of various subsets of lymphocytes and APCs
on lymphoid tissues has not been well-dissected. We ob-
served that whereas secondary lymphoid tissues increased
the efficiency of priming, they were not absolutely re-
quired. In our model, T cells were likely to be predomi-
nantly primed by APCs but not by tumor cells. Thus, our
data implies that APCs are able to carry antigens and mi-
grate to other peripheral sites to prime T cells.
Secondary lymphoid tissues were shown to be critical
for the rejection of MC57G tumor using alymphoplastic
(aly/aly) mice (9). However, our data indicated that they
are important but not essential using an identical tumor
line. However, apart from the absence of lymph nodes,
aly/aly mice host a variety of other serious immune defects
that may confound the findings, including depressed base-
line immunoglobulin production and isotype switching,
defective T cell function, and faulty homing response to
secondary lymphoid tissues (31–33). The inability to reject
the MC57G tumor in aly/aly mice might be explained by
additional defects in T cell functions, which might be con-
sistent with unchecked tumor growth in the absence of
CD4 help in our case. Although secondary lymphoid or-
gans undoubtedly play an important role in certain im-
mune responses, they may not play an essential role in oth-
ers (33). Using three murine models that are devoid of
lymph nodes, we have shown that tumor antigen–specific
CD8  T cells can still proliferate in the spleen in the ab-T
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sence of lymph nodes. CD8  T cells are able to proliferate
in response to and reject the tumor even when the hosts
lack all the secondary lymphoid organs, including the LN
and spleen. Interestingly, 2C T cell proliferation kinetics
was delayed but clearly detectable in the lungs of mice that
lack secondary lymphoid tissues, suggesting the peripheral
tissue could be alternative sites for indirect priming. Early
divisions of CFSE-labeled 2C T cells from collagenase-
digested lung tissues suggest that naive 2C cells might be
primed there. Unlike most other tissues, bronchial-associ-
ated lymphoid tissues may allow constitutive homing of
immune cells, including APCs and the naive T cell. Such
delayed priming of 2C cells in the lung may contribute to
eventual tumor rejection. Therefore, lymphoid tissues may
be more efficient in indirect priming but not absolute re-
quired in all cases.
CD4  T cells can help the priming of CD8  T cells in
many ways, such as providing soluble cytokines or mem-
brane ligands. They can recognize cognate antigens with
CD8  T cells during a helper-dependent CD8  T cell re-
sponse (30). We have evidence that MC57-SIY tumor cells
induce specific helper response that can be detected as early
as 3–4 d after a tumor challenge measured by DTH and
specific antibody response (unpublished data). However,
bystander CD4 help can also contribute to the activation of
CD8  T cells (31).
The CD4  T cell–dependent CD8  T cell response re-
vealed an important role for CD4  T cells in the activation
of APCs. Such activation on dendritic cells (DC) may en-
hance their expression of costimulatory molecules, pro-
duction of inflammatory cytokines, and migratory capacity
out of their resident peripheral compartments (32–34).
Our work has revealed that CD4  T cells are required for
the priming in the spleen but dispensable for that in the
DLN. There are several possible explanations. First, there
may be different types of APCs that carry antigens for sub-
cutaneously growing tumors. For example, it has been re-
ported that epidermal DC can only migrate to DLNs but
not the spleen (26). Other APCs that migrate to the spleen
or other peripheral sites might be dependent on CD4  T
cell activation. Second, enhanced migratory capacity of
DCs might be required for them to prime T cells in sites
other than DLN. This could be due to the differential
structures of LN and spleen or the unique position of the
DLN. Third, CD4  T cells may also provide some critical
cytokines and membrane ligands for the activation and
survival of CD8  T cells (16). When the conditions for
priming are not optimal, activation and survival signals
provided by CD4  T cells become critical for CD8  T
cell priming. Thus, helper T cells may be required for effi-
cient priming of CD8  T cells when antigens are limiting
or when DCs cannot efficiently interact with CD8  T
cells. Our preliminary findings suggested that CD40 sig-
naling can partially replace CD4  T cell function and re-
store the proliferation of antigen-specific CD8  T cells in
the spleen of LT  /  mice using agonistic anti-CD40 an-
tibody in CD4  T cell–depleted mice (unpublished data).
CD40 signal functioning directly on CD8  T cells has
been implicated to be essential for generation of memory
but not for initial proliferation (16). Thus, it is possible that
the complementary role of CD4  T cells for lack of DLN
involves activation of APCs.
In our tumor model, cross-priming of tumor antigen–
specific T cells is essential for efficient priming that leads to
tumor rejection. With the presence of helper T cells, prim-
ing of tumor antigen–specific CD8  T cells can efficiently
occur in the spleen. However, in the absence of CD4  T
cell help, local draining lymph nodes become essential for
the priming of CD8  T cells. Therefore, our paper reveals
the distinct interplay between T cells for cross-priming
CD8  T cells in the LN and the spleen.
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